- Current report filing (8-K)
October 18 2010 - 8:06AM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
:
October 15
, 2010
AVI
BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer
|
incorporation)
|
|
|
|
Identification No.)
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices, including zip code)
(425) 354-5038
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On
October 15, 2010, AVI BioPharma, Inc. issued a press release
announcing the results of a recently completed clinical trial of its product
candidate, AVI-4658, for the treatment of Duchenne Muscular Dystrophy
(DMD). The text of the press release is included as Exhibit 99.1 to
this Form 8-K and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit Number
|
|
Description
|
99.1
|
|
Press
Release
dated October 15,
2010 announcing results of clinical trial of AVI-4658.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
AVI BioPharma, Inc.
|
|
|
|
By:
|
/s/
J. David Boyle II
|
|
|
J. David Boyle II
|
|
|
Interim President and Chief Executive
Officer, and Senior Vice President and
Chief Financial Officer
|
Date:
October 16, 2010
3
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
99.1
|
|
Press
Release
dated October 15, 2010
announcing results of clinical trial of AVI-4658.
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024